Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


29. September 2020 | 10:51 CET

BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results

  • Health
Photo credits: pixabay.com

Investors' expectations of developments can drive the share price. When it comes to solving a problem or creating needs, the interest of the capital market is particularly high. Things get exciting for investors when the business model offers the possibilities of scalability. Attractive investment opportunities can be created in the fields of health and medicine, which offer extraordinary return opportunities.

time to read: 2 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


All signs point to success

BioNTech and Valeo Pharma are addressing the issue of the corona pandemic in two different ways. BioNTech is investing a lot of money in research, development, and testing to get a vaccine against Covid-19 ready for the market. The company is also simultaneously building up production capacities to be able to market the highest possible number of vaccine doses as quickly as possible. In the race for a vaccine, different interests come to the fore.

Of national interest

Whoever first brings a vaccine against Covid-19 onto the market will not only have demonstrated competence but will also pave a responsible way out of the restrictions for politicians and industry. Once a vaccine is available to the general public, it is the individual responsibility of citizens to ensure that the protective measure is implemented. The state has thus fulfilled its duty. Those who do not follow the advice and the solution are likely to be more or less left to their own devices, with the consequences.

Much upside, little downside

Valeo Pharma takes a different approach, as it does not carry out its research and development, but focuses on the marketing of drugs that have already been proven to be effective. Valeo Pharma usually works with smaller biotech companies whose focus and expertise is in research and development. With a portfolio of nine different compounds, the company can now generate revenues without being exposed to research risks. From the investors' perspective, this approach means diversified and steady growth.

Investors position themselves

In response to Covid-19, Valeo Pharma has recently launched the commercialisation of Hesperco. According to experts, the active ingredient contained in Hesperco strengthens the immune system and can therefore be used to prevent Covid-19. The product is particularly suitable for the target group that does not want to opt for vaccination and is considering alternative options as a replacement. The share price can gain 13.8% to CAD 1.32 in the run-up to the quarterly results. Operating results were announced today after the close of trading in Canada. The company has been invited to a conference call tomorrow, Wednesday 30 September 2020.

Waiting for the upturn

The Bayer Group, on the other hand, could not attract any attention for a specific active ingredient in the context of the Corona pandemic. However, the company is broadly positioned in the agricultural and pharmaceutical sectors and is expected to benefit in connection with an economic recovery in the coming year. Historically, the company's share is valued at around EUR 55.00, which is low and currently demands a great deal of patience and understanding from investors.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

09. February 2021 | 08:00 CET | by Stefan Feulner

CureVac, Cardiol Therapeutics, Bayer - roaring profits!

  • Health

The race for the best and most effective vaccine is in full swing. After BioNTech and its partner Pfizer, Moderna and AstraZeneca were approved in Europe, but there are always obstacles. Over the weekend, for example, South Africa announced that it is forgoing the AstraZeneca vaccine for the time being. The background to this is its supposedly lower efficacy with the B.1.351 virus mutation. Somewhat unnoticed, another vaccine manufacturer is moving into pole position through innovative collaborations.

Read

08. February 2021 | 07:30 CET | by Nico Popp

Fresenius, Fresenius Medical Care, Q&M Dental: Healthy returns await here

  • Health

Healthcare stocks have been in demand not just since the pandemic, but the pandemic is a sure game-changer for the industry in the long term. Demand for consumables and tests will continue to rise because this much seems certain: the Coronavirus will remain with us and possibly return year after year like a wave of influenza. Companies in the industry can profit from this. We present three stocks.

Read

28. January 2021 | 10:39 CET | by André Will-Laudien

Fresenius - Q&M Dental Group - IBU-tec: New price explosions every day!

  • Health

Rarely has the stock market been so volatile and exciting as in the last few days. Hedge fund Melvin Capital had to close out because of the GameStop share, and now the next wave is probably looming with AMC Entertainment. A full 270% went through the roof right at the opening; according to the New York Stock Exchange (NYSE) thousands of buy orders were already there at opening. Again, there had been a recommendation in a social media channel. On the Nasdaq, it jumped rapidly from USD 5 to USD 21 right at the opening - something you rarely see. And GameStop continues today after yesterday's debacle! After several trading suspensions, the value exploded further from USD 149 to USD 380 after a good hour of trading. That should have been the end of trading school for many new entrants!

Read